The Worms That Lived Longer Without Skipping a Meal
A roundworm about 0.04 inches (1 millimeter) long, a transparent, unsegmented tube with no legs and no face to speak of, lived roughly 19% longer after a dose of a drug sold for high blood pressure. It kept eating exactly as much as it always had. No skipped meals, no shrinking food supply, just a pill.
The worm is Caenorhabditis elegans, the standard laboratory nematode found in temperate soil on most continents, and the drug is rilmenidine, a cheap generic hypertension medication already prescribed to people. A team led by molecular biogerontologist João Pedro Magalhães at the University of Birmingham dosed C. elegans with rilmenidine at a concentration of 200 micromolar, starting treatment in some worms as young adults and in others only after they had already aged, and published the results in Aging Cell on January 20, 2023. Treated worms didn’t just live longer. They showed slower decline along the way, what the paper calls a healthspan effect, while growth and reproduction stayed untouched, a sign the drug was acting on aging itself rather than on development.
Why a Blood Pressure Switch Flips a Longevity Switch
The effect ran through a single receptor called nish-1. When Magalhães’ team deleted the nish-1 gene, rilmenidine stopped doing anything: treated worms lived no longer than untreated ones. When the researchers restored the gene, the lifespan extension came back. Delete it and lose the effect, restore it and get the effect back: that sequence is called a knockout-and-rescue experiment, and in biology it’s about as close to a smoking gun as evidence gets. Downstream of nish-1, treated worms ramped up autophagy, the cell’s internal cleanup crew that clears out damaged proteins, and handled heat stress better than worms that never got the drug.
The signal wasn’t a worm-only quirk. In mice, rilmenidine switched on gene-expression patterns in the liver and kidney that resembled patterns seen under actual caloric restriction, the practice of eating consistently less food. Different animal, different organs, same molecular fingerprint.
What Caloric Restriction Was Doing All Along
Caloric restriction is one of the most reliably reproduced ways to extend lifespan in laboratory animals, worms, flies, mice, and it has been studied for decades. Nobody who has tried it describes it as pleasant.
This study points somewhere else. In worms carrying a genetic mutation that already mimics caloric restriction, rilmenidine added nothing further. Giving the drug to worms already on restricted diets, or to worms with reduced signaling through TORC1, a growth-regulating pathway, or to worms given rapamycin, a drug that extends lifespan through that same pathway, produced no extra benefit either. The lifespan effect also required two proteins that switch genes on and off under stress, FOXO/DAF-16 and NRF1,2,3/SKN-1. All of it points the same way: the empty stomach was never the active ingredient. It was just the trigger for a resource-reallocation pathway that evolution built because repairing and maintaining tissue is a better bet during scarcity than aging on schedule. Hit the switch directly, and the starvation step turns out to be optional.
The Myth: You Have to Suffer For It
Caloric restriction has a reputation, earned across decades of animal and human trials, for being genuinely hard to sustain. The assumption riding along with it is that longevity and deprivation are a package deal, that you can’t have one without the other.
The nish-1 experiment contradicts that, at least in this worm. A drug that never touched how much the worms ate switched on what looks like the identical downstream pathway caloric restriction switches on: autophagy up, stress tolerance up, lifespan extended, with the receptor doing the work and the empty bowl nowhere in the picture. The myth that dies here is a narrow one. It isn’t “caloric restriction doesn’t work.” It’s “the restriction itself was the necessary ingredient.” In Caenorhabditis elegans, it wasn’t.
Worms Aren’t People, and Nobody’s Pretending Otherwise
Whether any of this carries over into human biology is genuinely unresolved, and contested even on the caloric-restriction side alone. Long-term controlled trials in people are difficult to run over a lifespan, and the results so far look far less dramatic than what shows up in worms and mice. Magalhães has been plain about where the work currently stands: early, with a long way left before rilmenidine’s relevance to human aging could be claimed with any confidence.
What he will say is why the question is worth chasing. “With a global aging population, the benefits of delaying aging, even if slightly, are immense,” he said, after his team showed, for the first time in any animal, that rilmenidine can increase lifespan. A real receptor, a real pathway, a real effect in a worm one millimeter long, and an honestly open question about what any of it means for anyone bigger.